Medical/Pharmaceuticals
Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with moderate-to-severe atopic dermatitis (AD), wi...
2025-07-29 20:00
2001
Leo Cancer Care Receives FDA 510(k) Clearance for Marie® - A Revolutionary Upright Radiotherapy Platform
MIDDLETON, Wis., July 29, 2025 /PRNewswire/ -- Leo Cancer Care, a leader in upright radiotherapy solutions, today announces that its flagship product, Marie®, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Marie represents a paradigm shift in the delivery of part...
2025-07-29 19:55
2767
ArisGlobal Achieves Strong Global Growth and Continued Innovation in First Half 2025
Expanding Impact of LifeSphere® NavaX™ Across the Industry, 27 Go-Lives, and New Global Pharma Adoptions BOSTON, July 29, 2025 /PRNewswire/ -- ArisGlobal, an AI-first technology company and creator of LifeSphere®, today announced significant momentum in the first half of 2025, driven by continue...
2025-07-29 19:21
2071
Fapon to Debut Shine mT8000 Open-Access, High Throughput Clinical Chemistry and Immunoassay Analyzer at ADLM 2025
CHICAGO, July 29, 2025 /PRNewswire/ -- Fapon, a global leading life sciences company, will debut its Shine mT8000 Fully Automated Clinical Chemistry and Immunoassay System at the ADLM 2025 Annual Scientific Meeting. This launch marks a significant milestone in Fapon's commitment to building an op...
2025-07-29 18:00
1959
WuXi Biologics Singapore CRDMO Hub Advances with the Launch of Modular Drug Product Facility Fabrication
* Innovative modular design will accelerate construction and manufacturing timelines, enabling rapid adaptation of manufacturing capacities across diverse product formats. * Finished building will be one of the world's largest modular biologics Drug Product (DP) facilities, and will enhance W...
2025-07-29 16:00
3373
Tigermed Completes Acquisition of Japanese CRO Micron
HANGZHOU, China and TOKYO, July 29, 2025 /PRNewswire/ -- Tigermed (300347.SZ / 3347.HK), a leading global provider of clinical research solutions across the full lifecycle of global biopharmaceutical and medical device products, today announces the completion of its acquisition of CRO company Mic...
2025-07-29 13:37
3036
Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Obtained Orphan Drug Designation from the U.S. FDA for the Treatment of GC/GEJ
SUZHOU, China, July 29, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and ga...
2025-07-29 10:37
1987
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: U.S. POINTER STUDY SHOWS STRUCTURED LIFESTYLE PROGRAM TARGETING MULTIPLE RISK FACTORS IMPROVES COGNITION IN OLDER ADULTS AT RISK OF COGNITIVE DECLINE
Key Takeaways * Two lifestyle interventions in U.S. POINTER improved cognition in older adults at risk of cognitive decline. A structured intervention with more support and accountability showed greater improvement compared to a self-guided intervention. * In a large, representative group of...
2025-07-29 02:39
2884
Siemens Healthineers Receives Frost & Sullivan's 2025 North America Company of the Year Award for Excellence in Advanced Visualization Applications
Recognized for delivering diagnostic innovation, workflow efficiency, and enterprise imaging leadership through advanced visualization solutions SAN ANTONIO, July 28, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to announce that Siemens Healthineers has been awarded the 2025 North America Co...
2025-07-28 22:00
2018
XellSmart Completed World's First Patient Dosing in its Registrational Clinical trial for iPSC-derived Subtype-specific Neural Cell Therapy for Spinal Cord Injury
SUZHOU, China, July 28, 2025 /PRNewswire/ -- XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. achieved a significant milestone in its "world's first" China NMPA & US FDA-approved registrational clinical trial. This Phase I China registrational clinical trial for XS228 Cell Injection – the ...
2025-07-28 21:10
2770
Big Lake Capital, LLC, Led and Controlled by NMHI CEO, Converts $671,984 Note into Nature's Miracle ("NMHI") Common Stocks
ONTARIO, Calif., July 28, 2025 /PRNewswire/ -- Nature's Miracle Holding Inc. (NMHI) ("Nature's Miracle" or the "Company"), a leader in vertical farming technology announce that Big Lake Capital, LLC (the "Investor"), an investment company led and controlled by CEO Tie "James" Li, converted$678,29...
2025-07-28 20:30
2343
World's First Engineered Exosome for Hair Growth & Localized Fat Reduction Secure INCI Designation: ImmVira Accelerates Access to Billion-Dollar Aging-related Market
SUZHOU, China, July 28, 2025 /PRNewswire/ -- ImmVira Group ("ImmVira" or the "Company")recently announced that its engineered exosome products MVR-EX104 ("EX104", for alopecia treatment) and MVR-EX105 ("EX105", for localized fat accumulation) have obtained International Nomenclature of Cosmetic I...
2025-07-28 20:28
2584
Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer's Association International Conference (AAIC)
Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting FREMONT, Calif., July 28, 2025 /PRNewswire/ -- Alamar Biosciences, a company pioneering precision proteomics to drive the earliest detection of disease, ...
2025-07-28 20:12
2460
Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug
- This approval for XPOVIO® in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy marks the third approved indication of the drug inChina. - XPOVIO® as a monotherapy in patients with relap...
2025-07-28 18:49
2514
Interventional Robot's RCT Research Published in JNIS, a Leading Journal in Neurointervention!
SHANGHAI, July 28, 2025 /PRNewswire/ -- The multicenter, randomized controlled trial (RCT) results of thePANVIS-A® NeuroInterventional Robotic System—led by ProfessorLiu Jianmin (Changhai Hospital) in collaboration with Professor Sun Jun (Wenzhou Central Hospital), ProfessorChen Wenhuo (Zhangzhou...
2025-07-28 18:35
1710
Embolx Launches Sniper G3: Revolutionizing Embolization with Enhanced Efficiency, Ease of Use, and Extended Shelf Life
SUNNYVALE, Calif., July 28, 2025 /PRNewswire/ -- Embolx, a leader in advanced microcatheters for targeted embolization procedures, today announced the release of its next-generation Sniper G3 Balloon Occlusion Microcatheter. This third iteration of the innovative device delivers significant enhan...
2025-07-28 18:00
1532
Caliway Announces FDA Clearance of IND Application for CBL-514 to Proceed with SUPREME-01, the First Global Pivotal Phase 3 Study for Reducing Abdominal Subcutaneous Fat
* CBL-514, Caliway's first-in-class lipolysis drug candidate, has been granted clearance from the U.S. FDA to proceed with SUPREME-01, a global, multicenter, pivotal Phase 3 study. Subject recruitment is expected to begin in the U.S. andCanada in Q3 2025. * CBL-514 is the first 505(b)(1) inve...
2025-07-28 17:51
1787
Successful Completion of First CRS with HIPEC on a 60-year-old Woman with Advanced Peritoneal Carcinomatosis
KOLKATA, India, July 28, 2025 /PRNewswire/ -- In a landmark achievement, a 60-year-old woman with advanced primary peritoneal carcinomatosis was successfully treated withCytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)at Manipal Hospital Dhakuria, under ...
2025-07-28 15:20
1655
Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'
* CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing EYLUXVI® to the reference product Eylea® * Upon approval, EYLUXVI® will be Alteogen's second biosimilar product, following a Herceptin® biosimilar by Alteogen's license partner Qilu Pharm...
2025-07-28 14:00
1867
MALAYSIA HEALTHCARE TRAVEL COUNCIL LAUNCHES MYMT 2026, MALAYSIA'S FIRST MEDICAL TOURISM YEAR
KUALA LUMPUR, Malaysia, July 28, 2025 /PRNewswire/ -- The Malaysia Healthcare Travel Council (MHTC) launchedMalaysia Year of Medical Tourism (MYMT) 2026 at the Malaysia International Trade and Exhibition Centre (MITEC). The Honourable Datuk Seri Dr. Dzulkefly Ahmad, Minister of Health Malaysia, ...
2025-07-28 12:17
2740
Week's Top Stories
Most Reposted
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 278 media titles]
2025-12-26 12:55ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 273 media titles]
2025-12-30 20:12
CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 262 media titles]
2025-12-29 09:00
ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 259 media titles]
2025-12-29 14:27